Novartis has bought biotech AveXis for $8.7 billion, adding a potential gene therapy for the rare disease spinal muscular atrophy (SMA) to its pipeline.
Takeda has raised eyebrows after announcing its intention to bid for UK pharma Shire, with analysts suggesting the Japanese pharma will have to overpay to clinch the deal.
